Sam Brusco, Associate Editor11.30.22
Electromed, a developer of airway clearance technologies, has gained U.S. Food and Drug Administration (FDA) 510(k) clearance for its fifth-generation SmartVest Clearway airway clearance system designed for high-frequency chest wall oscillation (HFCWO) therapy.
HFCWO helps clear the lungs of excess secretions to help reduce respiratory infection and hospitalization risks for patients with a chronic lung conditions. It delivers alternating air pulses into a vest garment, which quickly compresses and releases the chest wall, resulting in airflow oscillation in the airways. This movement acts to loosen, thin, and propel mucus toward major airways, where it can be expectorated.
SmartVest is indicated when external chest manipulation is the clinician’s treatment of choice to stimulate mucus transport. HFCWO therapy is typically prescribed for illnesses like non-cystic fibrosis bronchiectasis (NCFB) and other chronic pulmonary ailments.
“It is our goal to make home airway clearance easier and more convenient for patients, while continuing to provide a superior product, proven outcomes, and outstanding patient service,” Kathleen Skarvan, Electromed’s president and CEO told the press. “SmartVest Clearway meets these goals with its intuitive touch screen, the lightest weight generator on the market, and smaller footprint than our previous generation which continues our history of innovation in HFCWO therapy. We are proud to further our mission and assist more patients to breathe easier and improve their quality of life.”
HFCWO helps clear the lungs of excess secretions to help reduce respiratory infection and hospitalization risks for patients with a chronic lung conditions. It delivers alternating air pulses into a vest garment, which quickly compresses and releases the chest wall, resulting in airflow oscillation in the airways. This movement acts to loosen, thin, and propel mucus toward major airways, where it can be expectorated.
SmartVest is indicated when external chest manipulation is the clinician’s treatment of choice to stimulate mucus transport. HFCWO therapy is typically prescribed for illnesses like non-cystic fibrosis bronchiectasis (NCFB) and other chronic pulmonary ailments.
“It is our goal to make home airway clearance easier and more convenient for patients, while continuing to provide a superior product, proven outcomes, and outstanding patient service,” Kathleen Skarvan, Electromed’s president and CEO told the press. “SmartVest Clearway meets these goals with its intuitive touch screen, the lightest weight generator on the market, and smaller footprint than our previous generation which continues our history of innovation in HFCWO therapy. We are proud to further our mission and assist more patients to breathe easier and improve their quality of life.”